<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922218</url>
  </required_header>
  <id_info>
    <org_study_id>IBIMA-CNIO-CP-01-2016</org_study_id>
    <secondary_id>CNI-ENZ-2016-01</secondary_id>
    <nct_id>NCT02922218</nct_id>
  </id_info>
  <brief_title>PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in CRPC Patients Treated With Enzalutamide.</brief_title>
  <acronym>PROSENZA</acronym>
  <official_title>Prospective Multi-Centre Study of Prognostic Factors in Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROSENZA is a prospective multicentre study to analyse circulating and tissue biomarkers that
      may predict prognosis and response in patients with CRPC treated conventionally with
      Enzalutamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional prospective study in metastatic CRPC designed to explore
      biomarkers, composed by patients treated with Enzalutamide.

      Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented
      criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard
      treatment with enzalutamide.

      Primary end point: to study the prognostic value for overall survival (OS) of the detection
      of androgen receptor splicing variant 7 (AR-V7) and/or amplification of AR (AR+) in
      peripheral blood in this cohort.

      Secondary end points: a) to analyse the correlation between PSA response and AR-V7 and/or
      AR+; b) to evaluate the correlation between radiological response and AR-V7 and/or AR+; c) to
      study changes in AR-V7 frequency and/or AR+ pre and post ENZ; d) to analyse and correlate the
      prognostic role of AR-V7 and AR+ with other biomarkers as testosterone serum levels, PTENloss
      or TMPRSS-ERG fusions.

      Exploratory outcomes: a) to validate in this cohort prognostic nomograms described for CRPC;
      b) to validate the prognostic role of the expression signature described by Olmos et al
      (Lancet Oncol 2012) in peripheral blood; c)to explore new somatic and germinal variants in
      peripheral blood and tissue associated to dissemination, response and resistance to ENZ.

      PROSENZA is part of the PROCURE Biomarkers network, a multicentric spanish platform for
      biomarkers discovery in CRPC patients. 187 patients will be accrued to provide appropriate
      statistical power to analyse the main outcome. Blood samples are collected before, during
      (pre-cycle 3) and after progression to abiraterone acetate. Prospective data collection will
      be linked.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study the prognostic value of androgen receptor splicing variant 7 (AR-V7) and/or AR amplification in peripheral blood on overall survival in CRPC patients treated with Enzalutamide.</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the correlation between PSA response or radiological response with AR-V7 expression and/or AR amplification in CRPC patients treated with Enzalutamide.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze changes on AR-V7 expression and/or AR amplification before and after enzalutamide treatment.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the correlation between AR-V7 expression and AR amplification with other biomarkers as testosterone serum levels, PTEN loss or TMPRSS-ERG fusions in CRPC patients treated with Enzalutamide.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To validate in this patients the value of prognostic nomograms described for castration-resistant prostate cancer.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To validate the prognostic role of the expression signature in peripheral blood of 9 genes described by Olmos et al (Lancet Oncol 2012) on overall survival in CRPC patients treated with Enzalutamide.</measure>
    <time_frame>48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To explore the correlation between new somatic and germinal variants in peripheral blood and FFPE with response and resistance to Enzalutamide.</measure>
    <time_frame>48 months</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant</condition>
  <condition>Enzalutamide</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <description>Enzalutamide 160 mg/day c/24h</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and archival FFPE
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Castration-Resitant Prostate Cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed informed consent.

          2. Patients must be ≥ 18-year-old.

          3. Histologically confirmed prostate cancer.

          4. ECOG Performance Status ≤ 2.

          5. Castration resistance must be documented with surgical or medical castration with
             serum testosterone &lt; 50 ng/mL (&lt; 2.0 nm).

          6. Biochemical progresión upon prior treatment according to PCWG2 criteria.

          7. Candidates for standard treatment with enzalutamide 160 mg every 24 hours.

          8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy
             and/or radical prostatectomy.

          9. Acceptable haematological, hepatic and renal functions.

        Exclusion Criteria:

          1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
             and who are five years cancer-free or those diagnosed with skin cancers (of
             non-melanoma type) or excised in situ carcinomas.

          2. Any prior medical history that according to the judgement of the investigator might
             interfere with the subject´s granting of informed consent or the safe execution of the
             procedures required in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Olmos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CNIO-Centro Nacionald e Investigaciones Oncológicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Olmos, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2950</phone_ext>
    <email>dolmos@cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuria Romero, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2951</phone_ext>
    <email>prostac@cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Afonso, MD</last_name>
      <phone>+34981334000</phone>
      <email>Franciso.Javier.Afonso.Afonso@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urbano Anido, MD</last_name>
      <phone>+34981950000</phone>
      <email>urbanoanido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M. Piulats, MD</last_name>
      <phone>+34932607780</phone>
      <email>jmpiulats@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, MD</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3309</phone_ext>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Viciana, MD</last_name>
      <phone>+34956032075</phone>
      <email>ruthvician@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Villatoro, MD</last_name>
      <phone>+34951976470</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Lainez, MD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>5870</phone_ext>
      <email>nuria.lainez.milagro@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Delia Garcia, MD</last_name>
      <phone>+34922678204</phone>
      <email>rdgmarrero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Medina, MD</last_name>
      <phone>+34981287499</phone>
      <phone_ext>174</phone_ext>
      <email>ana.medina@cog.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>4695</phone_ext>
      <email>rafael.morales.barrera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Crespo, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Sanchez, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa, MD</last_name>
      <phone>+34926278000</phone>
      <phone_ext>77137</phone_ext>
      <email>jvillaguzman1@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Mendez, MD</last_name>
      <phone>+34957011147</phone>
      <email>mjosemv@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Luque, MD</last_name>
      <phone>+34958020000</phone>
      <email>rluquecaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Casinello, MD</last_name>
      <phone>+34949209200</phone>
      <email>jacaes@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Arranz, MD</last_name>
      <phone>+34914269070</phone>
      <email>jarranz@oncomed.gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <phone>347328000</phone>
      <phone_ext>2951</phone_ext>
      <email>nromerol@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Berta Nasarre, PhD</last_name>
      <email>bnasarre@cnio.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leticia Rivera, CRA senior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Grau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Pacheco, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Garces, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>7332</phone_ext>
      <email>docjavip@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellanos, MD</last_name>
      <phone>+34913908339</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Castro, MD</last_name>
      <phone>+34917328000</phone>
      <phone_ext>2950</phone_ext>
      <email>ecastro@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Medina, MD</last_name>
      <phone>+34951291425</phone>
      <email>msaez.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gonzalez, MD</last_name>
      <phone>+34968360900</phone>
      <phone_ext>3807</phone_ext>
      <email>engonbil@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Olmos, MD</last_name>
      <phone>34 91 732 8000</phone>
      <phone_ext>2950</phone_ext>
      <email>dolmos@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Gala Grau, PhD</last_name>
      <phone>34697959726</phone>
      <email>gala.gala.grau.eecc@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranzazu Gonzalez, MD</last_name>
      <phone>+34871206130</phone>
      <phone_ext>76130</phone_ext>
      <email>aranzazu.gonzalezdealba@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Azpitarte, MD</last_name>
      <phone>+34 986800004</phone>
      <email>crisazpi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lorente, MD</last_name>
      <phone>+34961244000</phone>
      <email>davlorente@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castration Resistant Prostate Cancer</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

